Sentences with phrase «treat ovarian cancers with»

Olaparib was approved by the FDA in 2014 to treat ovarian cancers with BRCA mutations.

They discovered that inhibitors of the protein EZH2 provided an effective strategy for treating ovarian cancers with elevated CARM1 expression.

Not exact matches

The drug is meant for women with advanced ovarian cancer who have already been treated with two or more chemotherapies.

By the time of diagnosis the majority of women with ovarian cancer already have extensive spread of the disease which makes it difficult to treat by surgery or chemotherapy.

«For this reason, we decided to combine vitamin C with a PARP inhibitor, a drug type known to cause cancer cell death by blocking the repair of DNA damage, and already approved for treating certain patients with ovarian cancer.»

«What we've discovered will help clinicians to better treat women with ovarian cancer,» says Dr. Ben Tsang, senior scientist at the Ottawa Hospital Research Institute and professor at the University of Ottawa.

«Pelvic RT after chemotherapy may be more beneficial in treating this form of ovarian cancer compared with other types,» Dr. Small said.

Ovarian cancer is typically treated with cisplatin, a platinum - based chemotherapy.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

The researchers treated 63 cancer cell lines (26 breast, 14 colorectal and 23 ovarian) with low - dose 5 - azacitidine (AZA), an FDA - approved drug for myelodysplastic syndrome, that reverses epigenetic changes by stripping off the methyl group that silences the gene.

In the Oncogene study, DrugPredict produced a prioritized list of 6,996 chemicals with potential to treat epithelial ovarian cancer.

A section of a tumor organoid grown from cells derived from a patient with high - grade serous ovarian cancer (left) and a mini-tumor treated with ReACp53, resulting in extensive cancer cell death.

«For decades, women have been treated with a combination of treatment options, resulting in poor prognosis for most women with advanced - stage ovarian cancer, but there are many survivors as well,» said Dr. Narod, senior scientist at Women's College Research Institute.

More than 80 percent of women with advanced stage high - grade serous ovarian cancer experience relapses even after repeated surgeries and multiple rounds of chemotherapy, and this effective new approach to treat the disease could be a major step forward in preventing cancer from returning.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratorycancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratorycancer patients treated at the Cancer Institute into laboratoryCancer Institute into laboratory mice.

The study reveals a mechanism that provides researchers with a promising target for treating ovarian and other metastatic cancers.

Though smaller in number, some patients with advanced disease and carrying a BRCA mutation may benefit from the same targeted therapy being used today in the clinic to successfully treat some ovarian cancer patients.»

Recent studies have shown that rucaparib, a PARP inhibitor, effectively treats patients with platinum - sensitive, relapsed, high - grade ovarian cancer harboring a BRCA mutation.

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study.

They found that the defect is highly sensitive to an existing FDA - approved drug used to treat ovarian cancer — a discovery that challenges current practice for treatment of brain tumors and other cancers with the same genetic defect, said the scientists.

Next they treated the experimental tumor cells with MIR506 to determine if it would behave in the same way it had with ovarian and other cancers.

At one hub of innovation, MIT's new Marble Center for Cancer Nanomedicine, researchers have taken aim at ovarian cancer with wide - ranging approaches, crafting nanoparticles designed to diagnose or treat the deadly diCancer Nanomedicine, researchers have taken aim at ovarian cancer with wide - ranging approaches, crafting nanoparticles designed to diagnose or treat the deadly dicancer with wide - ranging approaches, crafting nanoparticles designed to diagnose or treat the deadly disease.

With Hutch staff scientist Dr. John Lamb, Simon recently identified a compound that may improve on drugs that treat ovarian and other cancers.

In addition to being a member of CRI's Clinical Leadership Committee, Dr. Coukos is currently the lead investigator of a CRI - funded clinical trial that is treating ovarian cancer patients with two immunotherapies — MEDI4736, an anti-PD-L1 checkpoint inhibitor, and motolimod, a TLR8 agonist.

Dr. June: We have protocols that will be treating patients with mesothelioma, pancreatic cancer, and ovarian cancer, targeting a protein called mesothelin.

In that randomized, double - blind, placebo - controlled, phase III trial, 561 patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who were in complete or partial response to platinum - based chemotherapy were treated with either rucaparib 600 mg orally twice daily (372 patients) or to placebo (189 patients).

The LION trial randomized 650 patients with advanced epithelial ovarian cancer and macroscopic complete resection to either systematic pelvic and para-aortic LNE (323 patients in intention - to - treat cohort), or no LNE (324 patients in intention - to - treat cohort).

Cancer Network presents exclusive coverage on ovarian cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and trCancer Network presents exclusive coverage on ovarian cancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and trcancer from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, with reports on the latest clinical research changing the way ovarian cancer patients are being managed and trcancer patients are being managed and treated.

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.

Treating women with olaparib, a new type of experimental drug called a PARP inhibitor, after their initial cancer treatment, may help prevent their ovarian cancer from coming back, according to a phase - II clinical trial led by UK scientists.

At UT Southwestern Medical Center, our gynecologic cancer experts have unmatched expertise in treating patients with ovarian cancer.

May 20, 2015 Study adds diabetes drug with anti-cancer effect to ovarian cancer treatment Several recent studies have suggested that metformin, an established drug developed to treat patients with type II diabetes, may provide significant benefits, including increased survival, to patients being treated for advanced cancers.

Poznansky adds that the tumors that might be treated with the mesothelin - targeting vaccine — ovarian cancer, pancreatic cancer and mesothelioma — all have poor survival rates.

«Our study suggests a therapeutic benefit for repurposing a well - tolerated inhibitor with limited toxicity to treat a specific group of ovarian cancer patients with high levels of CARM1 expression,» said Sergey Karakashev, Ph.D., first author of the study and a postdoctoral researcher in the Zhang Lab.

That's because, compared with» lung and other hard - to - treat cancers (such as ovarian), breast cancer tends to be caught at earlier, more treatable stages, thanks to screenings like mammograms (which is why it's so important to get one every year, starting at age 40).

Study In 2006 Danish researchers at the University of Copenhagen published in the Scandinavian Journal of Medicine and Science in Sports the results of a study in which they had done experiments with a group of patients being treated for intestinal cancer, breast cancer, ovarian cancer and testicular cancer.

Other studies have shown that it can lower the risk of both pre - and postmenopausal breast cancers as well as ovarian cancers that are often difficult to treat with conventional medicine.